2-(4-bromo-2-chlorophenoxy)-N-cyclohexylacetamide | 430463-20-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(4-bromo-2-chlorophenoxy)-N-cyclohexylacetamide
• CAS: 430463-20-0
• 化学式: C₁₄H₁₇BrClNO₂
• 分子量: 346.651
• InChiKey: JXYZKTGGUJCRQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-bromo-2-chlorophenoxy)-N-cyclohexylacetamide 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 N-(3-(4-cyclohexyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)phenyl)-4-fluorobenzenesulfonamide
  参考文献：
  名称：

  Discovery of 4-phenyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors

  摘要：

  PI3K/Akt/mTOR signaling pathway plays an important role in cancer cell growth and survival. In this study, a new class of molecules with skeleton of 4-phenyl-2H-benzo[b] [1,4]oxazin-3(4H)-one were designed and synthesized targeting this pathway. Bioassays showed that, among all the molecules, 8d-1 was a pan-class I PI3K/mTOR inhibitor with an IC50 of 0.63 nM against PI3K alpha. In a wide panel of protein kinases assays, no off-target interactions of 8d-1 were identified. 8d-1 was orally available, and displayed favorable pharmacokinetic parameters in mice (oral bioavailability of 24.1%). In addition, 8d-1 demonstrated significant efficiency in Hela/A549 tumor xenograft models (TGI of 87.7% at dose of 50 mg/kg in Hela model) without causing significant weight loss and toxicity during 30 days treatment. Based on the bioassays, compound 8d-1 could be used as an anti-cancer drug candidate. (C) 2019 Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2019.06.021
• 作为产物：
  描述：

  环己胺 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 生成 2-(4-bromo-2-chlorophenoxy)-N-cyclohexylacetamide
  参考文献：
  名称：

  通过微笑重排法合成苯并[b] [1,4]恶嗪-3（4 H）-一抗微生物活性

  摘要：

  苯并[ b ] [1,4]恶嗪-3（4 H）-one衍生物1a – p，在苯环上带有F，Br和Cl或苄基，环己基，正己基和四呋喃基亚甲基通过Smiles重排合成与氮原子连接的分子，并在体外分析其对革兰氏阳性，革兰氏阴性细菌和真菌的抗菌活性。总体而言，苯并[ b ] [1,4]恶嗪-3（4 H）-1的抗菌活性对所有受测革兰氏阳性和革兰氏阴性微生物（MIC为16至64μg / ml），而对真菌的功效较弱。获得的数据表明，化合物中的氟原子1c，1f，1i在增强此类化合物的抗菌性能方面起着重要作用。这些观察结果提供了一些预测，以根据分子模型研究在合成之前进一步设计抗菌活性化合物。

  DOI：

  10.1007/s00044-010-9360-z

文献信息

• Synthesis of benzo[b][1,4]oxazin-3(4H)-ones via smiles rearrangement for antimicrobial activity
  作者：Liang Fang、Hua Zuo、Zhu-Bo Li、Xiao-Yan He、Li-Ying Wang、Xiao Tian、Bao-Xiang Zhao、Jun-Ying Miao、Dong-Soo Shin

  DOI：10.1007/s00044-010-9360-z

  日期：2011.7

  The benzo[b][1,4]oxazin-3(4H)-one derivatives, 1a–p, carrying F, Br, and Cl on the benzene ring, or benzyl, cyclohexyl, n-hexyl, and tetrafuryl methylene groups attached to nitrogen atom were synthesized via Smiles rearrangement and assayed in vitro for their antimicrobial activity against Gram-positive, Gram-negative bacteria, and fungi. The antimicrobial activity of the benzo[b][1,4]oxazin-3(4H)-ones

  苯并[ b ] [1,4]恶嗪-3（4 H）-one衍生物1a – p，在苯环上带有F，Br和Cl或苄基，环己基，正己基和四呋喃基亚甲基通过Smiles重排合成与氮原子连接的分子，并在体外分析其对革兰氏阳性，革兰氏阴性细菌和真菌的抗菌活性。总体而言，苯并[ b ] [1,4]恶嗪-3（4 H）-1的抗菌活性对所有受测革兰氏阳性和革兰氏阴性微生物（MIC为16至64μg / ml），而对真菌的功效较弱。获得的数据表明，化合物中的氟原子1c，1f，1i在增强此类化合物的抗菌性能方面起着重要作用。这些观察结果提供了一些预测，以根据分子模型研究在合成之前进一步设计抗菌活性化合物。
• Discovery of 4-phenyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors
  作者：Guoyi Yan、Chunlan Pu、Suke Lan、Xinxin Zhong、Meng Zhou、Xueyan Hou、Jie Yang、Huifang Shan、Lifeng Zhao、Rui Li

  DOI：10.1016/j.ejmech.2019.06.021

  日期：2019.9

  PI3K/Akt/mTOR signaling pathway plays an important role in cancer cell growth and survival. In this study, a new class of molecules with skeleton of 4-phenyl-2H-benzo[b] [1,4]oxazin-3(4H)-one were designed and synthesized targeting this pathway. Bioassays showed that, among all the molecules, 8d-1 was a pan-class I PI3K/mTOR inhibitor with an IC50 of 0.63 nM against PI3K alpha. In a wide panel of protein kinases assays, no off-target interactions of 8d-1 were identified. 8d-1 was orally available, and displayed favorable pharmacokinetic parameters in mice (oral bioavailability of 24.1%). In addition, 8d-1 demonstrated significant efficiency in Hela/A549 tumor xenograft models (TGI of 87.7% at dose of 50 mg/kg in Hela model) without causing significant weight loss and toxicity during 30 days treatment. Based on the bioassays, compound 8d-1 could be used as an anti-cancer drug candidate. (C) 2019 Published by Elsevier Masson SAS.